|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
M.D. Anderson Cancer Center Genentech |
| Information provided by: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00081861 |
Purpose
Phase II Study of Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma.
| Condition | Intervention | Phase |
|
Lymphoma |
Drug: Avastin (Bevacizumab) Drug: Rituximab |
Phase II |
| MedlinePlus related topics: | Cancer Lymphoma |
| Drug Information available for: | Rituximab Bevacizumab |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Texas | |||||
| UT MD Anderson Cancer Center | |||||
| Houston, Texas, United States, 77030 | |||||
| M.D. Anderson Cancer Center |
| Genentech |
| Principal Investigator: | Barbara Pro, MD | U.T. M.D. Anderson Cancer Center |
More Information
| Study ID Numbers: | 2003-0520 |
| First Received: | April 23, 2004 |
| Last Updated: | September 17, 2007 |
| ClinicalTrials.gov Identifier: | NCT00081861 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|